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Introduction
Alzheimer’s disease (AD) is the commonest cause of
dementia worldwide. However, no treatment is yet avail-
able to halt or reverse the underlying pathology of estab-
lished disease. Advances in the management of other
common diseases and an improvement in general health
have resulted in an increasingly elderly population so that
the prevalence of AD is expected to increase significantly
over time. In 2015, almost 47 million people worldwide
were estimated to be affected by dementia, with estimates
of 75 million by 2030, and 131 million by 2050, with the
greatest increase expected in low-income and middle-in-
come countries. The socio-economic burden of dementia
has become immense and the development of effective
interventions has become one of the greatest priorities for
health care research in the twenty-first century.
Current treatments for AD include acetyl cholinesterase
inhibitors and the N-methyl-D-aspartate receptor antago-
nist Memantine, but offer only symptomatic rather than
disease-modifying benefits. In spite of the urgent require-
ment, disease-modifying therapies have so far proved
elusive, in particular with almost universally disappointing
results in late stage clinical trials for therapies that target
aspects of amyloid metabolism. However, results from a
recent phase 1b trial, published in 2016, have offered new
hope. Aducanumab, a human monoclonal antibody that
selectively targets aggregated Ab, has been shown to
remove the build-up of the Alzheimer’s protein amyloid in
the brain and slow the decline in memory and thinking
skills in people with AD. This month’s journal club looks
at this and two other papers reporting recent clinical trials
in AD which together offer a window into potential future
therapeutic directions in this devastating disorder.
The antibody aducanumab reduces Ab plaques
in Alzheimer’s disease
This paper provides interim results from a double-blind,
placebo- controlled phase 1b randomized trial (PRIME). Its
primary outcome was to investigate safety, tolerability,
pharmacokinetics, and pharmacodynamics of monthly
infusions of aducanumab in patients with prodromal or
mild AD with brain Ab pathology confirmed by molecular
positron emission tomography (PET) imaging. 165 partic-
ipants were randomized across 33 centres to receive
monthly infusions of placebo, or 1, 3, 6, or 10 mg/kg doses
of aducanumab for 12 months. 40 patients dropped out,
leaving between 21 and 32 individuals per group for
analysis. The primary outcome was reduction in brain Ab
plaques as measured by florbetapir PET imaging in a dose-
and time-dependent fashion at baseline, six months, and
12 months. Additional cognitive tests were also performed
but were exploratory as the study was not powered to
detect clinical change.
At 6 and 12-month intervals there was a significant
dose-dependent reduction of Ab deposits. In the placebo
group, the florbetapir standardized average uptake value
ratio (SUVR) was 1.44, compared to 1.16 in the 10 mg/kg
group. The reduction in plaque load was seen in partici-
pants with both prodromal and mild AD, and regardless of
ApoE4 carrier status and reduced brain Ab in a dose- and
time-dependent manner. The most common adverse effects
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were amyloid-related imaging abnormalities (ARIA),
headache, urinary tract infection and upper respiratory tract
infection. ARIA-vasogenic oedema occurred in no patients
in the placebo group but up to 41% of the high dose group.
ARIA although not fully understood, generally occurred
early in the course of treatment and is likely to be related to
increased extracellular fluid, however, no patient were
hospitalised for this and there were no drug related deaths.
Comment and conclusion. Based on its primary out-
comes the PRIME study shows that aducanumab penetrates
the brain and decreases Ab in patients with AD in a time and
dose-dependent manner. With only 165 participants the
study was not powered to detect clinical change so that the
preliminary findings of a slowing of clinical decline mea-
sured by Clinical Dementia Rating (Sum of Boxes and Mini
Mental State Examination scores versus placebo at
12 months) must be interpreted with some caution. The
greatest effect in reducing brain Ab plaques was observed in
the 10 mg/kg group (p\ 0.05 versus placebo), and whereas
significant Ab reduction was detectable by 6 months, any
clinical effects were not seen until 12 months. Analysis also
suggested that performance on the CDR-SB and the MMSE
stabilized only in patients who had a substantial reduction in
amyloid at one year. Patients for whom there was no
reduction in imaging correlates of Ab levels, declined
cognitively in a similar pattern to the placebo group.
The authors acknowledged several study limitations of
the PRIME phase 1b study, including staggered parallel-
group design, small sample sizes, limited region (USAonly),
and possible partial unblinding due to the imaging frequency
required following ARIA. However, this study suggests that
a reduction of brain Abmay confer a clinical benefit, thereby
supporting the amyloid hypothesis and providing impetus to
research in this field, including unravelling the exact
molecular basis of clearance of Ab clearance from the brain
following aducanumab. The results from this Phase 1b study
support results from earlier preclinical trials demonstrating
aducanumab brain penetration, target engagement, and dose-
dependent clearance of Ab plaques, and if confirmed in
future studies powered to detect clinical benefit studies
would provide support for aducanumab as an Ab-removing,
disease-modifying therapy for AD.
Sevigny J et al (2016) Nature 537:50–56.
Efficacy and safety of tau-aggregation inhibitor
therapy in patients with mild or moderate
Alzheimer’s disease: a randomized, controlled,
double-blind, parallel-arm, phase 3 trial
Based on the previous potential efficacy of methylthion-
inium chloride in patients with AD, a modified stable re-
duced form of the methylthioninium moiety was identified
as a potential therapeutic agent. Leuco-methylthioninium
bishydromethanesulfonate (LMTM) acts as a selective
inhibitor of tau protein aggregation both in vitro and in
transgenic mouse models. The aim of this study was to
determine whether LMTM was safe and effective in
modifying disease progression in patients with mild to
moderate AD. The primary outcome measure was pro-
gression on the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog) and the AD Co-operative
Study-Activities of Daily Living Inventory (ADCS-ADL)
scales from baseline, assessed at week 65 in the modified
intention-to-treat population.
This was a large, multinational trial of 15 months
duration. It was a randomized, controlled, double-blind,
parallel-group trial involving 115 academic centres and
private research clinics in 16 countries in Europe, North
America, Asia, and Russia involving patients younger than
90 years with mild to moderate Alzheimer’s disease.
Patients taking other medicines for Alzheimer’s disease
were not excluded as the study group felt it infeasible not to
allow their inclusion. Participants were randomly assigned
(3:3:4) oral tablets to 75 mg LMTM twice a day, 125 mg
LMTM twice a day, or control (4 mg LMTM twice a day
to maintain blinding with respect to urine or faecal dis-
colouration). Randomisation was achieved via an interac-
tive web response system and all participants and all
assessors were masked to treatment assignment throughout
the study.
In total 891 participants were assigned to treatment (357
to control, 268–75 mg LMTM twice a day, and
266–125 mg LMTM twice a day). Neither co-primary
outcomes demonstrated treatment benefit at any dose:
ADAS-Cog score compared with control (n = 354, 6.32,
95% CI 5.31–7.34): 75 mg LMTM twice a day (n = 257)
-0.02, -1.60 to 1.56, p = 0.9834, 125 mg LMTM twice a
day (n = 250) -0.43, -2.06 to 1.20, p = 0.9323 and
change in ADCS-ADL score compared with control
(-8.22, 95% CI -9.63 to -6.82): 75 mg LMTM twice a
day -0.93, -3.12 to 1.26, p = 0.8659; 125 mg LMTM
twice a day -0.34, -2.61 to 1.93, p = 0.9479). The most
common adverse events were gastrointestinal and urinary
effects with both high doses of LMTM, and were the
commonest causes for discontinuation. Non-clinically sig-
nificant dose-dependent reductions in haemoglobin con-
centrations were the most commonly identified laboratory
abnormality. Amyloid-related imaging abnormalities were
noted in less than 1% (8/885) of participants.
Comment and conclusion. As with previous study’s
targeting tau protein accumulation analysis of the primary
outcomes for this study was negative and the results do not
suggest benefit of LMTM as an add-on treatment for
patients with mild to moderate Alzheimer’s disease.
Findings from a recently completed 18-month trial of
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patients with mild Alzheimer’s disease are to be released in
the near future.
Gauthier S et al (2016) The Lancet 388(10062):
2873–2884.
Towards personalised intervention in Alzheimer’s
disease
This final paper by Peng et al. is a review of the current
understanding of risk factors and intervention strategies in
AD and provides a practical alternative approach in
addressing the considerable challenges of treating patients
with Alzheimer’s. The authors suggest that these chal-
lenges commonly occur as a result of the heterogeneity in
disease aetiology, which involves complex and divergent
pathways and that more detailed patient stratification is
required to inform intervention strategies which can be
tailored for individual patients. They argue that this
approach would provide improved patient management
more focussed clinical trials and would also have potential
for more personalised intervention in AD.
The authors suggest that the required information that
would allow improved patient stratification centres on
demographic and biological data. The demographic data
includes APOE genotype, age, gender, education, envi-
ronmental exposure, life style, and medical history,
whereas the biological data might include genome
sequencing, imaging, biomarkers and functional assays on
patient-specific induced pluripotent cells. Intervention
strategies based on physical activity, brain stimulation,
social communication, diet and drugs are reviewed as well
as a stage specific intervention strategy.
Comment and conclusion. Admittedly intervention
strategies are limited currently and this review paper offers
a practical approach to modify risk factors and better target
preventative treatments. It is proposed that the demo-
graphic and in-depth information can also generate focus-
sed preventive strategies to limit the rate of conversion
from mild cognitive impairment to dementia.
Peng X et al (2016) Genomics Proteomics Bioinfor-
matics 14:289–297.
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